Default company panoramic image

CONTINUUS Pharmaceuticals

CONTINUUS Pharmaceuticals will enable “on-demand” manufacturing of pharmaceuticals with advantages in lead time, quality, and cost.

  • Stage Prototype Ready
  • Industry Healthcare Services
  • Location Boston, MA, USA
  • Currency USD
  • Founded January 2012
  • Employees 3
  • Website

Company Summary

CONTINUUS will produce medicines for the pharmaceuticals industry through an integrated continuous manufacturing (ICM) technology, and help save this industry billions of dollars every year. Medicines will be produced at significantly lower costs (> 50% cost reduction), with reduced lead times (99% reduction from industry standard), and of better quality in one single facility with a footprint of 1/10 compared to existing manufacturing plants.


  • Default avatar
    Salvatore Mascia, PhD
    Founder & CEO

    Salvatore Mascia was the former Strategic Project Manager at the Novartis-MIT Center for Continuous Manufacturing, where he led the integration of the ICM pilot plant. He holds a PhD in Chemical Engineering from the University of Cambridge, and a BS and MS in Pharmacy from University of Perugia. Salvatore co-founded “Professionisti Italiani a Boston” in 2009, and was President of the Cambridge University Technology and Enterprise Club in 2006/07.

  • Default avatar
    Bayan Teisho Takizawa, MD
    Co-Founder & Head of Business Development

    Bayan Takizawa is a co-Founder and Head of Business Development. He has experience in healthcare consulting (The Chartis Group) and venture capital (Actin Biomed). In addition, Bayan did a six month internship at Sandoz Pharmaceuticals, where he studied the economic benefits of a novel continuous chromatography technology. Bayan has an MD from Yale, an MS in Engineering Systems and MBA from MIT, and a BS in Chemical Engineering from Cornell.


  • Default avatar
    Sheppard Mullin Richter & Hampton LLP
    Default avatar
    Katz, Nannis + Solomon, PC

Previous Investors

  • Default avatar
    CONTINUUS raised $265 k in 5/2013 from angel investors in the Boston area.